Gb Sciences, Inc. (OTCQB:GBLX)

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations.

2023 Events

11th Annual Alzheimer's and Parkinson's Drug Development Summit February 21-23, 2023, San Francisco, CA
Neuroscience and Brain Disorders Forum 2023 March 27-28, 2023, London, UK and Online
PAINWeek Conference 2023 The National Conference on Pain for Frontline Practitioners September 5-8, 2023, Las Vegas

2022 Events

Alcor Drug Discovery Platform Summit May 12, 2022, Virtual
Neuro Forum Summit 2022 May 23, 2022, Virtual
The 5th Cannabinoid Derived Pharmaceuticals Summit Sept 7, 2022, Boston
Canna Pharma Conference Oct 12-13, 2022, San Diego
10th Drug Discovery Strategic Summit Oct 27-28, 2022, San Francisco
16th Precision in Drug Discovery/Preclinical Summit November 14, 2022, San Francisco

Most Recent Investor Presentation

Gb Sciences’ Drug Development Programs

Letter to Shareholder's

GBLX Stock Price

The GBLX stock price will be updated periodically, but there may be a lag with respect to real-time stock quotes

SEC Filings for Gb Sciences, Inc.

Latest News from Gb Sciences

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences’ COVID-19 Related Anti-Inflammatory Therapies

Gb Sciences Issues Shareholder Letter